We are live on
!
Find out more
First Trust Advisors Portfolio holdings
AUM
$140B
1-Year Est. Return
27.84%
This Fund
S&P 500
This Quarter
Est. Return
+7.26%
1 Year Est. Return
+27.84%
3 Year Est. Return
+78.79%
5 Year Est. Return
+98.89%
10 Year Est. Return
+456.9%
AUM
$29.6B
AUM Growth
+$4.22B
(+17%)
Cap. Flow
+$2.91B
Cap. Flow
% of AUM
9.83%
Top 10 Holdings %
Top 10 Hldgs %
7.91%
Holding
2,390
New
174
Increased
1,221
Reduced
844
Closed
147
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETF
HYLS
|
+$184M |
| 2 |
First Trust NYSE Arca Biotechnology Index Fund
FBT
|
+$158M |
| 3 |
First Trust Health Care AlphaDEX Fund
FXH
|
+$136M |
| 4 |
First Trust Dow Jones Internet Index Fund ETF
FDN
|
+$123M |
| 5 |
First Trust Consumer Staples AlphaDEX Fund
FXG
|
+$123M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$120M |
| 2 |
Conagra Brands
CAG
|
+$72.2M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
+$61.5M |
| 4 |
RAD
Rite Aid Corporation
RAD
|
+$55.9M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$50.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 12.87% |
| 3 | Consumer Discretionary | 10.2% |
| 4 | Consumer Staples | 9.25% |
| 5 | Industrials | 7.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vertex Pharmaceuticals
VRTX
$120B
| $121M | 0.41% |
1,016,236
+133,010
| +15% | +$15M |
|
27
Booking.com
BKNG
$134B
| $120M | 0.41% |
2,640,100
+33,075
| +1% | +$1.49M |
|
28
Pfizer
PFE
$143B
| $120M | 0.41% |
4,072,810
-302,333
| -7% | -$8.67M |
|
29
Kroger
KR
$34.2B
| $119M | 0.4% |
3,719,418
+1,315,470
| +55% | +$38.1M |
|
|
MDVN
30
DELISTED
MEDIVATION, INC.
MDVN
| $119M | 0.4% |
2,392,844
+1,061,808
| +80% | +$55.2M |
|
31
Microsoft
MSFT
$2.83T
| $117M | 0.4% |
2,525,338
+424,995
| +20% | +$19.9M |
|
32
IQVIA
IQV
$34.6B
| $115M | 0.39% |
1,954,492
+1,307,965
| +202% | +$74.6M |
|
33
Illumina
ILMN
$29.8B
| $113M | 0.38% |
629,368
-105,090
| -14% | -$18.5M |
|
34
Constellation Brands
STZ
$22.1B
| $112M | 0.38% |
1,138,209
+206,869
| +22% | +$18.9M |
|
35
Hain Celestial
HAIN
$49.1M
| $111M | 0.37% |
1,898,873
+1,268,041
| +201% | +$68.6M |
|
36
Salesforce
CRM
$129B
| $111M | 0.37% |
1,864,550
+160,151
| +9% | +$9.44M |
|
37
Netflix
NFLX
$287B
| $110M | 0.37% |
22,445,710
+4,479,020
| +25% | +$24M |
|
38
CVS Health
CVS
$136B
| $107M | 0.36% |
1,114,366
+317,486
| +40% | +$28M |
|
39
Monster Beverage
MNST
$91.5B
| $107M | 0.36% |
5,942,760
+5,537,340
| +1,366% | +$95.5M |
|
40
BioMarin Pharmaceuticals
BMRN
$11.4B
| $106M | 0.36% |
1,176,560
+21,164
| +2% | +$1.76M |
|
41
Charles River Laboratories
CRL
$11B
| $103M | 0.35% |
1,622,373
+1,238,910
| +323% | +$77.7M |
|
42
Archer Daniels Midland
ADM
$41.6B
| $102M | 0.34% |
1,955,913
+785,231
| +67% | +$39.2M |
|
|
PCYC
43
DELISTED
PHARMACYCLICS INC
PCYC
| $101M | 0.34% |
825,428
+105,305
| +15% | +$13.5M |
|
44
Keurig Dr Pepper
KDP
$40.4B
| $98.4M | 0.33% |
1,373,137
+511,256
| +59% | +$35.4M |
|
45
Equinix
EQIX
$102B
| $98.4M | 0.33% |
433,987
+53,990
| +14% | +$11.7M |
|
46
Bio-Techne
TECH
$11.2B
| $98.2M | 0.33% |
4,252,976
+782,168
| +23% | +$17.9M |
|
47
Pilgrim's Pride
PPC
$6.64B
| $98.2M | 0.33% |
2,995,071
+326,631
| +12% | +$10.3M |
|
48
Myriad Genetics
MYGN
$538M
| $98M | 0.33% |
2,876,422
-201,487
| -7% | -$7.15M |
|
|
WWAV
49
DELISTED
The WhiteWave Foods Company
WWAV
| $96.8M | 0.33% |
2,767,650
+231,675
| +9% | +$8.22M |
|
50
Spectrum Brands
SPB
$2.01B
| $96.8M | 0.33% |
1,011,298
+162,755
| +19% | +$14.8M |
|
Similar funds
DAM
First Trust Advisors's Q4 2014 Portfolio in Review
As of Q4 2014, First Trust Advisors held 2,390 positions worth $29.6B, up 17% from $25.4B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
First Trust Advisors deployed $2.91B of net new capital in Q4 2014, opening 174 new positions and adding to 1,221 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 857,683 shares worth $83.2M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was iShares iBoxx $ High Yield Corporate Bond ETF, an estimated $120M trimmed.
- First Trust Advisors's largest Q4 2014 buy was Alnylam Pharmaceuticals: 857,683 shares worth $83.2M.
- First Trust Advisors added most to First Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETF in Q4 2014, an estimated $184M increase.
- First Trust Advisors's biggest Q4 2014 reduction was iShares iBoxx $ High Yield Corporate Bond ETF, cutting an estimated $120M.
- First Trust Advisors fully exited Immunogen Inc in Q4 2014, selling an estimated $61.5M.
- First Trust Advisors's ten largest holdings make up 7.9% of its $29.6B portfolio in Q4 2014.
- First Trust Advisors opened 174 new positions and closed 147 in Q4 2014.
- First Trust Advisors's portfolio value rose 17% quarter-over-quarter to $29.6B.
Based on First Trust Advisors's 13F filing for Q4 2014, filed 13 Feb 2015.